Dalpiciclib in HR+/HER2- ABC

Shanghai Jiao Tong University

Status: Enrolling

Conditions: Advanced Breast Cancer

Treatments: Drug: dalpiciclib

Study type: Observational

Funder types: Other

Identifiers

NCT06301438

LY2024-022-A

Details and patient eligibility

About

To evaluate the efficacy and safety of dalpiciclib in patients with HR-positive/HER2-positive advanced breast cancer.

Enrollment: 103 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically confirmed advanced breast cancer
• Hormone receptor-positive and human epidermal growth factor receptor 2-negative
• ECOG 0-1

Exclusion criteria

• Pregnant or breastfeeding
• History of immunodeficiency

Trial design

103 participants in 1 patient group

dalpiciclib

Description:

dalpiciclib oral day 1-21, every 28 days

Treatment:

Drug: dalpiciclib